Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Gains from Investment Securities (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 7 years of Gains from Investment Securities readings, the most recent being $765514.0 for Q1 2026.

  • On a quarterly basis, Gains from Investment Securities rose 1463.23% to $765514.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $765514.0, a 1463.23% increase, with the full-year FY2025 number at $9.4 million, changed N/A from a year prior.
  • Gains from Investment Securities hit $765514.0 in Q1 2026 for Kiniksa Pharmaceuticals International, down from $1.1 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $11.6 million in Q3 2024 to a low of -$11.5 million in Q4 2023.
  • Median Gains from Investment Securities over the past 5 years was $765514.0 (2026), compared with a mean of $1.5 million.
  • Biggest five-year swings in Gains from Investment Securities: crashed 498.51% in 2023 and later soared 1463.23% in 2026.
  • Kiniksa Pharmaceuticals International's Gains from Investment Securities stood at $2.9 million in 2022, then crashed by 498.51% to -$11.5 million in 2023, then skyrocketed by 131.04% to $3.6 million in 2024, then crashed by 67.98% to $1.1 million in 2025, then crashed by 33.03% to $765514.0 in 2026.
  • The last three reported values for Gains from Investment Securities were $765514.0 (Q1 2026), $1.1 million (Q4 2025), and $941874.0 (Q3 2025) per Business Quant data.